Home LiteratureArticle Details
PMID: 23177934 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells.

Cell metabolism ·Vol. 16 ·No. 6 ·2012-12-05 ·Pages 751-64

Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, Snell C, Steers G, Turley H, Li JL, Günther UL, Buffa FM, McIntyre A, Harris AL

Abstract

Metabolic reprogramming of cancer cells provides energy and multiple intermediates critical for cell growth. Hypoxia in tumors represents a hostile environment that can encourage these transformations. We report that glycogen metabolism is upregulated in tumors in vivo and in cancer cells in vitro in response to hypoxia. In vitro, hypoxia induced an early accumulation of glycogen, followed by a gradual decline. Concordantly, glycogen synthase (GYS1) showed a rapid induction, followed by a later increase of glycogen phosphorylase (PYGL). PYGL depletion and the consequent glycogen accumulation led to increased reactive oxygen species (ROS) levels that contributed to a p53-dependent induction of senescence and markedly impaired tumorigenesis in vivo. Metabolic analyses indicated that glycogen degradation by PYGL is important for the optimal function of the pentose phosphate pathway. Thus, glycogen metabolism is a key pathway induced by hypoxia, necessary for optimal glucose utilization, which represents a targetable mechanism of metabolic adaptation.

MeSH Terms
Angiogenesis Inhibitors/pharmacology Animals Antibodies, Monoclonal, Humanized/pharmacology Bevacizumab Breast Neoplasms/metabolism,pathology Cell Hypoxia/drug effects Cell Line, Tumor Cell Proliferation/drug effects Cellular Senescence/drug effects Female Glucose/pharmacology Glycogen/metabolism Glycogen Phosphorylase/antagonists & inhibitors,genetics,metabolism Glycogen Synthase/metabolism HCT116 Cells Humans MCF-7 Cells Mice Mice, Nude RNA Interference RNA, Small Interfering/metabolism Reactive Oxygen Species/metabolism Transplantation, Heterologous Tumor Suppressor Protein p53/metabolism
Chemicals
Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized RNA, Small Interfering Reactive Oxygen Species Tumor Suppressor Protein p53 Bevacizumab Glycogen Glycogen Phosphorylase Glycogen Synthase Glucose
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Favaro Elena
Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Bensaad Karim
Chong Mei G
Tennant Daniel A
Ferguson David J P
Snell Cameron
Steers Graham
Turley Helen
Li Ji-Liang
Günther Ulrich L
Buffa Francesca M
McIntyre Alan
Harris Adrian L
Article Info
Journal
Cell metabolism
Abbr.
Cell Metab
ISSN
1932-7420
Published
2012-12-05
Epub
2012-00-21
Pages
751-64
Language
English
Region
United States
NLM ID
101233170
Subset
IM
Grants
Cancer Research UK · 11359 · United Kingdom
Department of Health · NF-SI-0611-10163 · United Kingdom
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com